1-{5-[3-(2-chloro-4-methylphenyl)pyridin-4-yl]-1,3-thiazol-2-yl}-2-methylpropan-1-one

ID: ALA5275331

Max Phase: Preclinical

Molecular Formula: C19H17ClN2OS

Molecular Weight: 356.88

Names and Identifiers

Canonical SMILES:  Cc1ccc(-c2cnccc2-c2cnc(C(=O)C(C)C)s2)c(Cl)c1

Standard InChI:  InChI=1S/C19H17ClN2OS/c1-11(2)18(23)19-22-10-17(24-19)14-6-7-21-9-15(14)13-5-4-12(3)8-16(13)20/h4-11H,1-3H3

Standard InChI Key:  PURJEHNDMPZCCY-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 26  0  0  0  0  0  0  0  0999 V2000
    1.8822    1.1272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6280    0.7745    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6947   -0.0452    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0163   -0.5151    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2734   -0.1657    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2011    0.6555    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.4549    1.0081    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2234    0.5383    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8869    1.0570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6175    1.8163    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.2114    1.7918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5587   -0.5783    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.5585   -1.4037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1543   -1.8144    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8692   -1.4017    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8708   -0.5805    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1589   -0.1640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2732   -1.8163    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -1.5839   -1.8143    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.6841    0.8434    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8976    0.0463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2676    1.4269    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3141   -0.5371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6947   -0.1671    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  1  6  1  0
  6  5  2  0
  6  7  1  0
  8  7  1  0
  8  9  1  0
  9 10  2  0
 11 10  1  0
  7 11  2  0
 12  5  1  0
 13 12  2  0
 14 13  1  0
 15 14  2  0
 16 15  1  0
 12 17  1  0
 17 16  2  0
 13 18  1  0
 15 19  1  0
  9 20  1  0
 20 21  1  0
 20 22  2  0
 21 23  1  0
 21 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5275331

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 356.88

Molecular Weight (Monoisotopic): 356.0750

AlogP: 5.67

#Rotatable Bonds: 4

Polar Surface Area: 42.85

Molecular Species: NEUTRAL

HBA: 4

HBD: ┄

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): 1

CX Acidic pKa: ┄

CX Basic pKa: 3.51

CX LogP: 5.00

CX LogD: 5.00

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.57

Np Likeness Score: -0.76

References

1. Manetti F..  (2018)  Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials.,  155  [PMID:29908439] [10.1016/j.ejmech.2018.06.016]

Source

Source(1):

• Scientific Literature